Matthew Plunkett, EVP, Chief Business Officer at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.14 ($12K) on 2016-02-04, disclosed to the SEC on 2016-02-05.
Scheduled sale ($12k) by EVP, Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.14 | 400 | $456 | 3.9% |
| 2 | $1.15 | 5,000 | $6K | 49.8% |
| 3 | $1.16 | 600 | $696 | 6.0% |
| 4 | $1.16 | 3,000 | $3K | 30.1% |
| 5 | $1.17 | 700 | $819 | 7.1% |
| 6 | $1.18 | 300 |
| $354 |
| 3.1% |
| Total | $1.16 avg | 10,000 | $12K | 100% |
| Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-11-06 | $14K | — | Filing → |
| CTIC | SELL | 2015-10-07 | $15K | — | Filing → |